COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome
Ilana Levy, Avital Lavi, Eran Zimran, Sigal Grisariu, Shlomzion Aumann, Gilad Itchaki, Tamar Berger, Pia Raanani, Reut Harel, Ariel Aviv, Noa Lavi, Tsila Zuckerman, Lev Shvidel, Osnat Jarchowsky, Martin Ellis, Katrin Herzog Tzarfati, Maya Koren‐Michowitz, Yehonatan Sherf, Itai Levi, Orit Sofer, Ofer Shpilberg, Nagib Dally, Celia Suriu, Andrei Braester, Sharon Ben Barouch, Merav Leiba, Daniela Goldstein, Nadav Sarid, Shay Yeganeh, Jabour Halloun, Moshe Mittelman, Tamar Tadmor
Abstract
= 0.021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit. In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective.